November 2025

• Comprehensive multiple risk factor control in cancer survivors to mitigate heart failure risk: insights from a prospective cohort study

In this large UK Biobank cohort, comprehensive control of eight modifiable risk factors was strongly associated with lower heart failure (HF) risk among cancer survivors. Each additional controlled factor reduced HF risk by 12%, and achieving ≥5 controls brought HF risk close to that of non-cancer controls. Cancer type, chemotherapy, smoking, BMI, and physical activity were the dominant determinants. These findings highlight the importance of proactive, comprehensive cardiovascular risk management in cancer survivorship. Implementing structured strategies to optimise blood pressure, metabolic health, weight, smoking cessation, and physical activity could substantially reduce long-term heart failure risk and help close the risk gap with non-cancer populations.

• Framingham risk score associates with incident cancer and heart failure
• Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors
• Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment
  
  

October 2025 :

• Diet and Prevention of Cardiovascular Disease and Cancer 

Certain foods have well-established links to increased cancer risk. A recent literature review by Hull and colleagues highlights evidence-based strategies to improve nutrition and shared dietary risk factors to prevent occurrence and recurrence of cardiovascular disease and cancer. The study shows that the best diet for cancer prevention consists of unprocessed plant foods, for example fruits, vegetables, legumes, nuts, and whole grains, while reducing the intake of meat, processed food, and sweets.

• Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study | European Heart Journal | Oxford Academic
• SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial
• Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma: JACC: CardioOncology State-of the-Art Review

September 2025 :

• Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study

This national-scale analysis of >170,000 patients treated with ICIs confirms that ICI-related myotoxicities are rare but highly lethal early events, often cardio-muscular in nature. It pinpoints risk-enriched phenotypes (thymic malignancy, neuromuscular comorbidity, combination ICIs, very advanced age), supporting risk-adapted surveillance and rapid triage rather than blanket screening of all ICI recipients.

• Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial
• Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial)

August 2025 :

• Cardiovascular safety of a standardized outpatient triage and diagnostic approach for suspected cardiovascular immune-related adverse events of immune checkpoint inhibitors 

This prospective cohort study evaluated the safety of a structured outpatient triage approach for suspected cardiovascular immune-related adverse events (CV-irAEs) in patients receiving immune checkpoint inhibitors (ICIs). Conducted between March 2022 and October 2023, it included 175 adults, of whom 83% were managed as outpatients using the FAST-TRACK ICI safety checklist. This protocol excluded patients with cardiovascular symptoms, abnormal ECG, dual ICI therapy, or significant pre-existing disease from outpatient care. Most referrals (64%) were for asymptomatic troponin elevation. No cardiovascular deaths occurred within 30 days among outpatients, demonstrating the approach’s safety. Overall, 54% had confirmed CV-irAEs, and 41% were diagnosed with myocarditis. Prior cardiovascular disease (OR 2.52) and impaired global longitudinal strain (<16%, OR 2.18) were significantly associated with CV-irAEs. Findings suggest that with structured triage by oncologists, many suspected CV-irAEs can be safely managed outside hospital settings, optimizing resources while maintaining patient safety.

• Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy.
• The EHJ supplements, Volume 27 Issue Supplement_6

July 2025 :

• Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology. 

The statement from the European Society of Cardiology (ESC) — including the Heart Failure Association, the European Association of Preventive Cardiology, and the ESC Council of Cardio-Oncology — addresses:

1. Definition & epidemiology of cancer therapy–related cardiac dysfunction (CTRCD)
2. Risk stratification of patients by means of the IC-OS HFA score
3. Diagnostic pathways for early detection
4. Prevention strategies: lifetime lifestyle but nuanced pharmacological interventions in high risk patients for CTRCD primary prevention
5. A holistic cardio-oncology management model for both short- and long-term care

• Predictors of Long‐Term Survival in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis. 
• Early Rhythm Control of Atrial Fibrillation in Cancer Survivors: A Nationwide Population‐Based Study. 

June 2025 :

•  Immune checkpoint inhibitor-associated myocarditis: a novel risk score

Immune checkpoint inhibitor (ICI)-induced myocarditis is a serious complication of cancer immunotherapy, and may lead to significant long-term cardiac complications, such as arrhythmias and heart failure. The mortality rate is up to 50% in affected patients. In a recently published multicenter, retrospective registry study by Power and colleagues, 757 patients from 17 countries were enrolled diagnosed with ICI myocarditis. The study aimed to identify predictors of severe outcomes in ICI myocarditis and to develop a risk score to help clinicians in risk stratification and treatment decisions. The authors found that the magnitude of troponin increase, pre-existing thymoma, presence of cardiomuscular symptoms, reduced left ventricular ejection fraction <50%, and ECG with low QRS voltage were associated with severe cardiomyotoxicity, and may be a promising tool in identifying patients who could be safely managed by withholding ICI therapy.

• Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis | European Heart Journal | Oxford Academic
• 3. External validation of the Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in cancer patients | European Journal of Preventive Cardiology | Oxford Academic

May 2025 :

• Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM)

The study titled "Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM)" by Higashikuni et al., published in the Journal of the American College of Cardiology: CardioOncology on May 13, 2025, explores innovative strategies to counteract the cardiotoxic effects of doxorubicin, a widely used chemotherapeutic agent known for its potential to cause heart damage. The study identifies miR-222 and miR-455 as a potent miRNA combination capable of reducing doxorubicin-induced cardiotoxicity. These findings highlight the potential of combinatorial miRNA therapies and the utility of CombiGEM technology in discovering novel cardioprotective strategies.

• Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis 

April 2025 :

• Increased cancer incidence in patients with pre-existing heart failure: results from a French nationwide cohort study

The current knowledge on reverse cardio-oncology is limited. It remains unclear whether patients with pre-existing heart failure are at increased risk of developing cancer considering that they share common risk factors. In a recent large French nationwide cohort study by Mirabel and colleagues (doi: 10.1093/eurjpc/zwaf152) including over 330 000 patients with established heart failure, patients with pre-existing heart failure demonstrated a 16% higher attributable risk of new-onset cancer, particularly lung, colon and blood cancers, regardless of known risk factors. These findings emphasize and support the need for cancer screening strategies among patients with pre-existing heart failure.

• Coronary inflammation and cardiovascular risk in breast cancer after radiotherapy
• Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer 
• Hemoglobin A1c stratifies risk of adverse cardiovascular outcomes in prostate cancer survivors in the UK Biobank: a cohort study
• History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial
• Identification of Anticancer Drugs Associated With Cancer Therapy-Related Cardiac Dysfunction in Pediatrics—Analysis of the WHO Pharmacovigilance Database

March 2025 :

• Impact of sodium-glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis.

By means of a systematic review and meta(analysis of the literature, Bhalraam and colleagues assessed the cardioprotective effect of SGLT2i on heart failure in patients treated for cancer. The results that included 13 studies and >80,000 participants suggest that SGLT2i reduces heart failure incidence and need for hospital. The group of patients who may benefit the most from SGLT2i are breast cancer patients treated with anthracylines. Overall, SGLT2i are promising cardioprotective drugs to prevent either cancer therapy-related cardiac dysfunction or overt heart failure. Randomized controlled studies are however needed at this stage.

• Outcomes of patients with cancer admitted with heart failure–associated cardiogenic shock .  
• Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
• An update on the European Society of Cardiology Council of Cardio-Oncology. 
• Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. 
• Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy.

February 2025 :

• Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score

This study validates the Heart Failure Association (HFA) and International Cardio-Oncology Society (IC-OS) risk score for predicting anthracycline-induced cardiovascular toxicity. Analyzing real-world data, the authors assess its accuracy in identifying high-risk patients, enhancing prevention strategies. Findings support its clinical utility in guiding cardio-oncology management. The study highlights the importance of risk stratification in optimizing anthracycline therapy while minimizing cardiovascular complications.

• Mobile/wearable digital devices for care of active cancer patients: a survey from the ESC Council of Cardio-Oncology 

This survey by the ESC Council of Cardio-Oncology explores the role of mobile and wearable digital devices in managing active cancer patients. It assesses their adoption, benefits, and barriers in monitoring cardiovascular health. Results highlight the potential of digital tools to improve early detection, patient engagement, and personalized care. However, challenges such as data integration and regulatory issues remain, requiring further standardization for widespread implementation.

January 2025 :

• Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial

The SUCCOUR-MRI trial assessed whether cardioprotective therapy guided by early detection of reduced global longitudinal strain (GLS) during anthracycline chemotherapy could better preserve left ventricular ejection fraction (LVEF). In 333 patients, those with isolated GLS impairment received either cardioprotective therapy or usual care. Results showed that cardioprotective therapy significantly reduced declines in LVEF. Its potential to improve cardiovascular clinical outcomes needs further research.

• Breast cancer and cardiovascular health

December 2024 : 

• Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α

Authors explore pathways of myocyte toxicity due to antharcyclines by means of a translational study  including a murine animal model and replicated on cardiomyocytes from a single leukemia patient. Their results increase our knowledge on the pathways of anthracyclin cardiotoxicity. Authors test the effect of  IL-1α neutralizing antibodies with a positive effect on the murine model. Although their results need further research in humans, it opens new perspectives for cardioprotection beyond the classic heart failure therapies.

• Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study
• Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer 

November 2024 :

• Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score
• Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)